Connecticut 2016 Regular Session

Connecticut Senate Bill SB00352

Introduced
3/2/16  
Introduced
3/2/16  
Refer
3/2/16  
Report Pass
3/21/16  
Report Pass
3/21/16  
Refer
3/29/16  

Caption

An Act Concerning Prescriptions For And The Dispensing Of Opioid Antagonists And Opioid Drugs.

Impact

The passage of SB 00352 is expected to significantly impact state laws regarding the prescription and dispensing of opioid medications. By allowing pharmacists to prescribe opioid antagonists, the bill encourages broader community access to these drugs, potentially reducing the number of fatal overdoses. Moreover, the requirement for pharmacists to provide training on the use of these medications is aimed at ensuring safety and efficacy in their administration, thus making strides towards better public health outcomes related to opioid use.

Summary

Senate Bill 00352 aims to enhance the availability and regulation of opioid antagonists, primarily focusing on preventing opioid overdoses. The bill grants pharmacists the authority to prescribe opioid antagonists via standing orders given by licensed practitioners, enabling individuals at risk of opioid overdose, as well as their family and friends, to obtain these life-saving medications without a prior patient-specific prescription. It emphasizes the role of pharmacists in both prescribing and providing education on the administration of opioid antagonists, thus expanding access to these critical interventions.

Sentiment

The general sentiment surrounding SB 00352 appears to be supportive among healthcare providers and public health advocates, who view it as a necessary measure to combat the ongoing opioid crisis. However, there are concerns regarding the potential for misuse of opioid prescriptions, particularly with the seven-day limit imposed for initial prescriptions to adults and minors. This reflects a recognition of the delicate balance required in improving access to essential medications while mitigating the risks of addiction and abuse.

Contention

Notable points of contention include the strict limitations on prescribing opioids to minors and the conditions under which practitioners can exceed the seven-day prescription cap for adults. Opponents may argue that such regulations could hinder the effective treatment of patients with chronic pain or lead to inappropriate prescribing practices if not carefully monitored. Balancing access and safety in the implementation of these provisions presents an ongoing challenge for legislators and healthcare providers.

Companion Bills

No companion bills found.

Similar Bills

HI SB2030

Relating To Prescription Drugs.

AZ SB1211

Pharmacists; prescribing; naloxone; reporting

MI HB5078

Health: pharmaceuticals; distribution of opioid antagonists by employees and agents of agencies under the administration of opioid antagonists act; provide for. Amends sec. 17744b of 1978 PA 368 (MCL 333.17744b).

MI HB4365

Health: pharmaceuticals; distribution of opioid antagonists by employees and agents of agencies under the administration of opioid antagonists act; provide for. Amends sec. 17744b of 1978 PA 368 (MCL 333.17744b). TIE BAR WITH: HB 4366'23

HI HB1038

Relating To The Electronic Prescription Accountability System.

HI SB1192

Relating To The Electronic Prescription Accountability System.

HI SB2033

Relating To The Electronic Prescription Accountability System.

CA SB1259

Pharmacists: furnishing opioid antagonists.